

Moderator



Dr. Stephen Sammut

Founder and President,
Pangea University for the
Health Sciences

Speakers



Mr. Gregg Alton

EVP Corporate and Medical
Affairs, Gilead



**Ms. Kiran
Mazumdar-Shaw**

Chairperson and Managing
Director, Biocon Limited



Mark Wu

Assistant Professor,
Harvard Law School



Dr. Girish Sahni

Director General, Council of
Scientific & Industrial
Research (CSIR), Govt. of
India

BIO International Convention 2018

June 4 -7, Boston, USA

Session on : Balancing Access to Medicines in the Developing World with the Realities of Pharmaceutical Development

Date: 4 June 2018

Time: 2:30 – 3:45 pm

Venue: BCEC, Room 210A, Level 2

If there is one issue that has vexed almost all stakeholders in the Pharmaceuticals space it is undoubtedly Drug Pricing , the salience of which doesn't seem to be abating any time soon. Each year several new medicines hit the market with prices that run into hundreds of thousands of dollars. This causes fresh waves in already choppy waters. Several developing countries have made cheaper medicines as the main plank for improving access. While drug developers point out to the increasing costs of novel drug development, many others argue that the real cost is far less. Some governments in the developing world rationalize that drug prices should be much lower than what the developers are charging. Panelists from the public and private sector organizations will try and find an acceptable solution to balance various perspectives.



Educational access and above categories of registrations required